{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:51:17Z","timestamp":1784332277320,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR AR063120"],"award-info":[{"award-number":["K24 AR AR063120"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10067-022-06206-y","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T12:05:37Z","timestamp":1652875537000},"page":"3049-3054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The clinical relevance of Raynaud\u2019s phenomenon symptom characteristics in systemic sclerosis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4909","authenticated-orcid":false,"given":"Michael","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"6206_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","volume":"50","author":"M Bassel","year":"2011","unstructured":"Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD (2011) Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 50:762\u2013767","journal-title":"Rheumatology (Oxford)"},{"key":"6206_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna DK (2017) Systemic sclerosis. Lancet 390:1685\u20131699","journal-title":"Lancet"},{"key":"6206_CR3","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","volume":"38","author":"JD Pauling","year":"2019","unstructured":"Pauling JD, Hughes M, Pope JE (2019) Raynaud\u2019s phenomenon - an update on diagnosis, classification and management. Clin Rheumatol 38:3317\u20133330","journal-title":"Clin Rheumatol"},{"key":"6206_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","volume":"4","author":"M Hughes","year":"2020","unstructured":"Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerrinic M et al (2020) Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 4:208\u2013221","journal-title":"Nat Rev Rheumatol"},{"key":"6206_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"FM Wigley","year":"2016","unstructured":"Wigley FM, Flavahan NA (2016) Raynaud\u2019s phenomenon. N Engl J Med 375:556\u2013565","journal-title":"N Engl J Med"},{"key":"6206_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/rheumatology\/key026","volume":"58","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D (2018) The patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Rheumatolology (Oxford) 58:18\u201326","journal-title":"Rheumatolology (Oxford)"},{"key":"6206_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2014-205897","volume":"75","author":"C Mihai","year":"2016","unstructured":"Mihai C, Landew\u00e9 R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM et al (2016) Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75:681\u2013686","journal-title":"Ann Rheum Dis"},{"key":"6206_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/rheumatology\/keab510","volume":"61","author":"M Hughes","year":"2022","unstructured":"Hughes M, Heal C, Henes J, Balbir-Gurman A, Distler JHW, Air\u00f2 P et al (2022) Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford) 61:1141\u20131147","journal-title":"Rheumatology (Oxford)"},{"key":"6206_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953\u20131962","journal-title":"Arthritis Rheum"},{"key":"6206_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/acr.23729","volume":"71","author":"JD Pauling","year":"2019","unstructured":"Pauling JD, Reilly E, Smith T, Frech TM (2019) Evolving symptom characteristics of Raynaud\u2019s phenomenon in systemic sclerosis and their association with physician and patient-reported assessments of disease severity. Arthritis Care Res (Hoboken) 71:1119\u20131126","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6206_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/acr.23475","volume":"70","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H et al (2018) A multi-national qualitative research study exploring the patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Care Res (Hoboken) 70:1373\u20131384","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6206_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","volume":"40","author":"S Murphy","year":"2021","unstructured":"Murphy S, Lescoat A, Alore M, Hughes M, Pauling JD, Sabbagh M et al (2021) How do patients define Raynaud\u2019s phenomenon? Differences between primary and secondary disease. Clin Rheumatol 40:1611\u20131616","journal-title":"Clin Rheumatol"},{"key":"6206_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/rheumatology\/kev002","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM (2015) Herrick AL (2015) Prediction and impact of attacks of Raynaud\u2019s phenomenon, as judged by patient perception. Rheumatology (Oxford) 54:1443\u20131447","journal-title":"Rheumatology (Oxford)"},{"key":"6206_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/acr.24710","volume":"73","author":"M Hughes","year":"2021","unstructured":"Hughes M, Huang S, Pauling JD, Sabbagh M, Khanna D (2021) Factors influencing patient decision-making concerning treatment escalation in Raynaud\u2019s phenomenon secondary to systemic sclerosis. Arthritis Care Res (Hoboken) 73:1845\u20131852","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6206_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/rheumatology\/kez522","volume":"59","author":"M Hughes","year":"2020","unstructured":"Hughes M, Khanna DK, Pauling JD (2020) Drug initiation and escalation strategies of vasodilator therapies for Raynaud\u2019s phenomenon: can we treat to target? Rheumatology (Oxford) 59:464\u2013466","journal-title":"Rheumatology (Oxford)"},{"key":"6206_CR16","first-page":"1):e000782","volume":"1;4(Suppl","author":"V Smith","year":"2019","unstructured":"Smith V, Scir\u00e8 CA, Talarico R, Airo P, Alexander T, Allanore Y et al (2019) Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open 1;4(Suppl:1):e000782","journal-title":"RMD Open"},{"key":"6206_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.41669","volume":"73","author":"D Khanna","year":"2021","unstructured":"Khanna D, Zhao C, Saggar R, Mathai SC, Chung LS, Coghlan JG et al (2021) Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries. Arthritis Rheumatol 73:837\u2013847","journal-title":"Arthritis Rheumatol"},{"key":"6206_CR18","doi-asserted-by":"publisher","unstructured":"Hughes M, Zanatta E, Sandler RD, Avouac J, Allanore Y (2021) Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. Rheumatology (Oxford) https:\/\/doi.org\/10.1093\/rheumatology\/keab850. [Online ahead of print]","DOI":"10.1093\/rheumatology\/keab850"},{"key":"6206_CR19","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"6206_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3899\/jrheum.150382","volume":"43","author":"P Moinzadeh","year":"2016","unstructured":"Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N et al (2016) Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol 43:66\u201374","journal-title":"J Rheumatol"},{"key":"6206_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10067-019-04564-8","volume":"39","author":"J Blagojevic","year":"2020","unstructured":"Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S et al (2020) Use of vasoactive\/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clin Rheumatol 39:27\u201336","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06206-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T14:26:45Z","timestamp":1663597605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["6206"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06206-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved with exempt status by the University of Michigan IRB (Study ID: HUM00175143; OHRP IRB Registration Number(s): IRB00000246).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Michael Hughes\u2014reports speaking fees from Actelion pharmaceuticals, Eli Lilly, and Pfizer, outside of the submitted work (all <$10,000). He is a member of a Data and Safety Monitoring Board for Certa Therapeutics. Suiyuan Huang\u2014no reported conflicts of interest or competing interests. John Pauling\u2014reports personal fees from Boehringer Ingelheim, Astra Zenaca, Sojournix Pharma and Permeatus Inc.; grants, personal fees, and non-financial support from Janssen; all outside the submitted work (<$10,000 for all honoraria \/ speaker fees). Maya Sabbagh\u2014no reported conflicts of interest or competing interests. Dinesh Khanna\u2014consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech\/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus, Theraly; Dr. Khanna is Chief Medical Officer of Eicos Sciences, Inc, a subsidiary of CiviBioPharma and has stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}